The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group-Reference-Cited by-同舟云学术

The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group

Published:2018-09-07 Issue:4 Volume:36 Page:693-700
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Papageorgiou Sotirios G.¹^ORCID,Kontos Christos K.²^ORCID,Kotsianidis Ioannis³⁴,Vasilatou Diamantina¹,Symeonidis Argyris⁴⁵,Galanopoulos Athanasios⁴⁶,Bouchla Anthi¹,Hatzimichael Eleftheria⁷,Repousis Panagiotis⁸,Zikos Panagiotis⁹,Viniou Nora-Athina⁴¹⁰,Poulakidas Elias¹¹,Vassilakopoulos Theodoros P.¹²,Diamantopoulos Panagiotis¹⁰^ORCID,Diamantopoulos Marios A.²,Mparmparousi Despoina¹³,Bouronikou Eleni¹⁴,Papadaki Helen¹⁵,Panayiotidis Panayiotis¹⁶,Pappa Vasiliki¹⁴

Affiliation:

1. Second Department of Internal Medicine and Research Unit; University General Hospital “Attikon”; Athens Greece

2. Department of Biochemistry and Molecular Biology; University of Athens; Athens Greece

3. Department of Hematology, Democritus University of Thrace Medical School; University Hospital of Alexandroupolis; Alexandroupolis Greece

4. The Hellenic (Greek) MDS Study Group; Athens Greece

5. General University Hospital of Patras; Patras Greece

6. General Hospital of Athens ‘G. Gennimatas’; Athens Greece

7. University Hospital of Ioannina; Ioannina Greece

8. Department of Hematology; ‘Metaxa’ Piraeus Cancer Hospital; Piraeus Greece

9. General Hospital of Patras ‘Agios Andreas’; Patras Greece

10. First Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece

11. ‘401’ Army General Hospital of Athens; Athens Greece

12. Department of Haematology; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece

13. Department of Clinical Therapeutics; National and Kapodistrian University of Athens, School of Medicine; Athens Greece

14. University General Hospital of Larissa; Larissa Greece

15. University General Hospital of Heraklion; Heraklion Greece

16. First Propaedeutic Department of Internal Medicine; National and Kapodistrian University of Athens; Athens Greece

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2551/fullpdf

Reference11 articles.

1. Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges;Bejar;Am Soc Clin Oncol Educ Book,2013

2. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management;Garcia-Manero;Am J Hematol,2014

3. NCCN Guidlines 2017

4. How we treat higher-risk myelodysplastic syndromes;Sekeres;Blood,2014

5. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study;Fenaux;Blood,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?;Leukemia;2023-10-10

2. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms;The Cancer Journal;2023-05

3. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes;Blood;2023-02-01

4. MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?;Cancers;2022-09-01

5. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine;Epigenomics;2021-07